Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab.

MLA

Kikuchi, Tatsuya, et al. “Predictive Factors for Transition to Conversion Therapy in Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab.” Liver International, vol. 44, no. 6, June 2024, pp. 1456–63. EBSCOhost, https://doi.org/10.1111/liv.15907.

APA

Kikuchi, T., Takeuchi, Y., Nouso, K., Kariyama, K., Kuwaki, K., Toshimori, J., Iwado, S., Moriya, A., Hagihara, H., Takabatake, H., Tada, T., Yasunaka, T., Sakata, M., Sue, M., Miyake, N., Adachi, T., Wada, N., Onishi, H., Shiraha, H., & Takaki, A. (2024). Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab. Liver International, 44(6), 1456–1463. https://doi.org/10.1111/liv.15907

Chicago

Kikuchi, Tatsuya, Yasuto Takeuchi, Kazuhiro Nouso, Kazuya Kariyama, Kenji Kuwaki, Junichi Toshimori, Shota Iwado, et al. 2024. “Predictive Factors for Transition to Conversion Therapy in Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab.” Liver International 44 (6): 1456–63. doi:10.1111/liv.15907.